Literature DB >> 19006550

Hemicrania continua evolving from cluster headache responsive to valproic acid.

Giorgio Lambru, Paola Castellini, Annamaria Bini, Andrea Evangelista, Gian Camillo Manzoni, Paola Torelli.   

Abstract

Hemicrania continua (HC) is a rare type of primary headache characterized by a prompt and enduring response to indomethacin. We describe a patient who suffered from cluster headache evolving into ipsilateral HC, who does not tolerate a long-term indomethacin therapy. The case was complex in terms of diagnosis, associated comorbidity, and choice of treatment; after several trials with different therapeutic regimens, we started the patient on a therapy with valproic acid and obtained an improvement of her HC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19006550     DOI: 10.1111/j.1526-4610.2008.01249.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  5 in total

Review 1.  When indomethacin fails: additional treatment options for "indomethacin responsive headaches".

Authors:  Shuhan Zhu; Brian McGeeney
Journal:  Curr Pain Headache Rep       Date:  2015-03

Review 2.  Focus on therapy: hemicrania continua and new daily persistent headache.

Authors:  Paolo Rossi; Cristina Tassorelli; Marta Allena; Enrico Ferrante; Carlo Lisotto; Giuseppe Nappi
Journal:  J Headache Pain       Date:  2010-02-26       Impact factor: 7.277

Review 3.  Therapeutical approaches to paroxysmal hemicrania, hemicrania continua and short lasting unilateral neuralgiform headache attacks: a critical appraisal.

Authors:  Carlo Baraldi; Lanfranco Pellesi; Simona Guerzoni; Maria Michela Cainazzo; Luigi Alberto Pini
Journal:  J Headache Pain       Date:  2017-07-20       Impact factor: 7.277

Review 4.  Hemicrania continua: clinical review, diagnosis and management.

Authors:  Sanjay Prakash; Payal Patel
Journal:  J Pain Res       Date:  2017-06-29       Impact factor: 3.133

Review 5.  Hemicrania Continua.

Authors:  Sanjay Prakash; Bansi Adroja
Journal:  Ann Indian Acad Neurol       Date:  2018-04       Impact factor: 1.383

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.